Antibodies in oncology

New Biotechnology

Volumn 28, Issue 5, 2011, Pages 518-529

  Pillay, Vinochani ^a   Gan, Hui K ^a   Scott, Andrew M ^a,b  

^a AUSTIN HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; CELLULAR PATHWAY; CLINICAL DEVELOPMENT; CLINICAL ONCOLOGY; CLINICAL TRIAL; CYTOTOXIC AGENTS; DIFFERENT MECHANISMS; HOST IMMUNE RESPONSE; HUMAN MALIGNANCIES; MONOCLONAL ANTIBODIES (MABS); NEW THERAPEUTIC AGENT; TARGETED DELIVERY;

CELL DEATH; DISEASES; MONOCLONAL ANTIBODIES; TUMORS;

ONCOLOGY;

ADECATUMUMAB; ALEMTUZUMAB; BEVACIZUMAB; BRENTUXIMAB VEDOTIN; CAPECITABINE; CETUXIMAB; CISPLATIN; ETERACIZUMAB; FARLETUZUMAB; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GIRENTUXIMAB; IBRITUMOMAB TIUXETAN; LABETUZUMAB; MINRETUMOMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CC49; MONOCLONAL ANTIBODY J591; NIMOTUZUMAB; OFATUMUMAB; OREGOVOMAB; PANITUMUMAB; PEMTUMOMAB; PERTUZUMAB; RITUXIMAB; TOSITUMOMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLOCIXIMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIANGIOGENIC ACTIVITY; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; B LYMPHOCYTE; BREAST CANCER; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER THERAPY; CHRONIC LYMPHATIC LEUKEMIA; COLON CANCER; COLON TUMOR; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONJUGATE; EPITHELIUM TUMOR; EXPERIMENTAL MODEL; GLIOBLASTOMA; GLIOMA; HEAD AND NECK CARCINOMA; HEAD AND NECK TUMOR; HODGKIN DISEASE; HUMAN; HYBRIDOMA; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; KIDNEY CARCINOMA; LIGAND BINDING; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG TUMOR; LYMPHOMA; METASTATIC COLORECTAL CARCINOMA; MYELOMA CELL; NEOPLASM; NON SQUAMOUS NON SMALL CELL LUNG CANCER; NONHODGKIN LYMPHOMA; NONHUMAN; ONCOLOGY; OVARY TUMOR; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE TUMOR; REVIEW; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STOMACH CARCINOMA; TUMOR CELL; TUMOR GROWTH;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOLOGIC TECHNIQUES; NEOPLASMS;

MURINAE;

EID: 80052808921     PISSN: 18716784     EISSN: 18764347     Source Type: Journal    
DOI: 10.1016/j.nbt.2011.03.021     Document Type: Review

References (144)

1. Köhler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256:495-497.
2. Reichert J.M., et al. Monoclonal antibody successes in the clinic. Nat. Biotechnol. 2005, 23:1073-1078.
3. Reichert J.M., Valge-Archer V.E. Development trends for monoclonal antibody cancer therapeutics. Nat. Rev. Drug Discov. 2007, 6:349-356.
4. McCafferty J., et al. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990, 348:552-554.
5. Hudson P.J., Souriau C. Engineered antibodies. Nat. Med. 2003, 9:129-134.
6. Lonberg N. Human antibodies from transgenic animals. Nat. Biotechnol. 2005, 23:1117-1125.
7. Ober R.J., et al. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int. Immunol. 2001, 13:1551-1559.
8. Shawler D.L., et al. Human immune response to multiple injections of murine monoclonal IgG. J. Immunol. 1985, 135:1530-1535.
9. Kuus-Reichel K., et al. Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies?. Clin. Diagn. Lab. Immunol. 1994, 1:365-372.
10. Kipps T.J., et al. Importance of immunoglobulin isotype in human antibody-dependent, cell-mediated cytotoxicity directed by murine monoclonal antibodies. J. Exp. Med. 1985, 161:1-17.
11. Jones P.T., et al. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986, 321:522-525.
12. Stern M., Herrmann R. Overview of monoclonal antibodies in cancer therapy: present and promise. Crit. Rev. Oncol. Hematol. 2005, 54:11-29.
13. Morrison S.L., et al. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. U.S.A. 1984, 81:6851-6855.
14. Riechmann L., et al. Reshaping human antibodies for therapy. Nature 1988, 332:323-327.
15. Chothia C., et al. Conformations of immunoglobulin hypervariable regions. Nature 1989, 342:877-883.
16. Nelson A.L., et al. Development trends for human monoclonal antibody therapeutics. Nat. Rev. Drug Discov. 2010, 9:767-774.
17. Chirino A.J., et al. Minimizing the immunogenicity of protein therapeutics. Drug Discov. Today 2004, 9:82-90.
18. Hwang W.Y., Foote J. Immunogenicity of engineered antibodies. Methods 2005, 36:3-10.
19. Holliger P., Hudson P.J. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 2005, 23:1126-1136.
20. Beckman R.A., et al. Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer 2007, 109:170-179.
21. Hudson P.J. Recombinant antibody constructs in cancer therapy. Curr. Opin. Immunol. 1999, 11:548-557.
22. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer 2001, 1:118-129.
23. Adams G.P., Weiner L.M. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 2005, 23:1147-1157.
24. Weiner L.M., et al. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 2010, 10:317-327.
25. Clynes R.A., et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 2000, 6:443-446.
26. Cartron G., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002, 99:754-758.
27. Weng W.K., Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 2003, 21:3940-3947.
28. Musolino A., et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J. Clin. Oncol. 2008, 26:1789-1796.
29. Bibeau F., et al. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J. Clin. Oncol. 2009, 27:1122-1129.
30. Ferris R.L., et al. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J. Clin. Oncol. 2010, 28:4390-4399.
31. Kubota T., et al. Engineered therapeutic antibodies with improved effector functions. Cancer Sci. 2009, 100:1566-1572.
32. Sarnaik A.A., Weber J.S. Recent advances using anti-CTLA-4 for the treatment of melanoma. Cancer J. 2009, 15:169-173.
33. Hamann P.R., et al. A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts. Bioconjug. Chem. 2005, 16:354-360.
34. Boghaert E.R., et al. Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-acetyl gamma calicheamicin dimethyl hydrazide targets Lewisy and eliminates Lewisy-positive human carcinoma cells and xenografts. Clin. Cancer Res. 2004, 10:4538-4549.
35. Herbertson R.A., et al. Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers. Clin. Cancer Res. 2009, 15:6709-6715.
36. Deckert P.M. Current constructs and targets in clinical development for antibody-based cancer therapy. Curr. Drug Targets 2009, 10:158-175.
37. Hughes B. Antibody-drug conjugates for cancer: poised to deliver?. Nat. Rev. Drug Discov. 2010, 9:665-667.
38. Lewis Phillips G.D., et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008, 68:9280-9290.
39. Younes A., et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N. Engl. J. Med. 2010, 363:1812-1821.
40. Sunada H., et al. Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc. Natl. Acad. Sci. U.S.A. 1986, 83:3825-3829.
41. Li S., et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005, 7:301-311.
42. Jungbluth A.A., et al. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:639-644.
43. Chen J.S., et al. Strategies to target HER2/neu overexpression for cancer therapy. Drug Resist. Updat. 2003, 6:129-136.
44. Hudis C.A. Trastuzumab-mechanism of action and use in clinical practice. N. Engl. J. Med. 2007, 357:39-51.
45. Badache A., Hynes N.E. A new therapeutic antibody masks ErbB2 to its partners. Cancer Cell 2004, 5:299-301.
46. Scheuer W., et al. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009, 69:9330-9336.
47. Schoeberl B., et al. Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci. Signal. 2009, 2:ra31.
48. Salgaller M.L. Technology evaluation: bevacizumab, Genentech/Roche. Curr. Opin. Mol. Ther. 2003, 5:657-667.
49. Ellis L.M., Hicklin D.J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 2008, 8:579-591.
50. Kirkwood J.M., et al. Next generation of immunotherapy for melanoma. J. Clin. Oncol. 2008, 26:3445-3455.
51. Canadas I., et al. C-MET as a new therapeutic target for the development of novel anticancer drugs. Clin. Transl. Oncol. 2010, 12:253-260.
52. Fox N.L., et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-1 and receptor-2 agonists for cancer therapy. Expert Opin. Biol. Ther. 2010, 10:1-18.
53. Yada A., et al. A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes. Ann. Oncol. 2008, 19:1060-1067.
54. Carles J., et al. Management and interpretation of novel toxicities of molecular targeted therapies: renal toxicities. Eur. J. Cancer 2009, 45(Suppl. 1):309-317.
55. Segaert S., et al. Skin toxicities of targeted therapies. Eur. J. Cancer 2009, 45(Suppl. 1):295-308.
56. Strevel E.L., Siu L.L. Cardiovascular toxicity of molecularly targeted agents. Eur. J. Cancer 2009, 45(Suppl. 1):318-331.
57. Asnacios A., et al. Gastrointestinal toxicities of novel agents in cancer therapy. Eur. J. Cancer 2009, 45(Suppl. 1):332-342.
58. Friedman H.S., et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 2009, 27:4733-4740.
59. Norden A.D., et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008, 70:779-787.
60. Wierda W.G., et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J. Clin. Oncol. 2010, 28:1749-1755.
61. Larson R.A., et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005, 104:1442-1452.
62. Horning S.J., et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J. Clin. Oncol. 2005, 23:712-719.
63. Kaminski M.S., et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J. Clin. Oncol. 2001, 19:3918-3928.
64. Van Cutsem E., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 2009, 360:1408-1417.
65. Bokemeyer C., et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 2009, 27:663-671.
66. Amado R.G., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008, 26:1626-1634.
67. Khambata-Ford S., et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol. 2007, 25:3230-3237.
68. Karapetis C.S., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 2008, 359:1757-1765.
69. Lievre A., et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 2008, 26:374-379.
70. Witzig T.E., et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 2002, 20:2453-2463.
71. Hodi F.S., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363:711-723.
72. Royal R.E., et al. Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J. Immunother. 2010, 33:828-833.
73. Yang J.C., et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J. Immunother. 2007, 30:825-830.
74. O'Mahony D., et al. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin. Cancer Res. 2007, 13:958-964.
75. Small E.J., et al. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin. Cancer Res. 2007, 13:1810-1815.
76. Ansell S.M., et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin. Cancer Res. 2009, 15:6446-6453.
77. Reichert J.M. Antibody-based therapeutics to watch in 2011. mAbs 2010, 3:1-24.
78. Haluska P., et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin. Cancer Res. 2007, 13:5834-5840.
79. Karp D.D., et al. Continued high activity of figitumumab (CP-751,871) combination therapy in squamous lung cancer. J. Clin. Oncol. 2010, 28. abstr 8072.
80. Jassem J., et al. Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). J. Clin. Oncol. 2010, 28. abstr 7500.
81. Gualberto A., et al. Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition. Clin. Cancer Res. 2010, 16:4654-4665.
82. Fields A.L.A., et al. Adjuvant therapy with the monoclonal antibody edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer. J. Clin. Oncol. 2009, 27:1941-1947.
83. Berek J., et al. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J. Clin. Oncol. 2009, 27:418-425.
84. Weiner G.J. Rituximab: mechanism of action. Semin. Hematol. 2010, 47:115-123.
85. Leonard J.P. Targeting CD20 in follicular NHL: novel anti-CD20 therapies, antibody engineering, and the use of radioimmunoconjugates. Hematology Am. Soc. Hematol. Educ. Program 2005, 335-339.
86. Stasi R. Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia. Expert Opin. Biol. Ther. 2008, 8:527-540.
87. Robak T. Alemtuzumab for B-cell chronic lymphocytic leukemia. Expert Rev. Anticancer Ther. 2008, 8:1033-1051.
88. Munz M., et al. Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies. Cancer Cell Int. 2010, 10:44.
89. Blumenthal R.D., et al. In vitro and in vivo anticancer efficacy of unconjugated humanized anti-CEA monoclonal antibodies. Br. J. Cancer 2008, 99:837-838. (author reply 839-840).
90. Scott A.M., et al. A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake. Clin. Cancer Res. 2005, 11:4810-4817.
91. Heath J.K., et al. The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:469-474.
92. Beatson R.E., et al. MUC1 immunotherapy. Immunotherapy 2010, 2:305-327.
93. Berek J.S. Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab. Expert Opin. Biol. Ther. 2004, 4:1159-1165.
94. Yoon S.O., et al. Construction, affinity maturation, and biological characterization of an anti-tumor-associated glycoprotein-72 humanized antibody. J. Biol. Chem. 2006, 281:6985-6992.
95. Davis I.D., et al. A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma. Cancer Immun. 2007, 7:14.
96. Nanus D.M., et al. Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J. Urol. 2003, 170:S84-88. (discussion S88-89).
97. Spannuth W.A., et al. Farletuzumab in epithelial ovarian carcinoma. Expert Opin. Biol. Ther. 2010, 10:431-437.
98. van Zanten-Przybysz I., et al. Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study. J. Cancer Res. Clin. Oncol. 2002, 128:484-492.
99. Scott A.M., et al. Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma. Cancer Immun. 2005, 5:3.
100. Kushner B.H., et al. Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J. Clin. Oncol. 2001, 19:4189-4194.
101. Scott A.M., et al. Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors. Cancer Res. 2000, 60:3254-3261.
102. Scott A.M., et al. A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen. Clin. Cancer Res. 2007, 13:3286-3292.
103. Kristeleit H. IGN-311. Igeneon. Curr. Opin. Investig. Drugs 2005, 6:1272-1279.
104. Mukherji S.K. Bevacizumab (Avastin). Am. J. Neuroradiol. 2010, 31:235-236.
105. Ton N.C., et al. Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2. Clin. Cancer Res. 2007, 13:7113-7118.
106. Hersey P., et al. A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma. Cancer 2010, 116:1526-1534.
107. Kuwada S.K. Drug evaluation: volociximab, an angiogenesis-inhibiting chimeric monoclonal antibody. Curr. Opin. Mol. Ther. 2007, 9:92-98.
108. Vincenzi B., et al. Cetuximab: from bench to bedside. Curr. Cancer Drug Targets 2010, 10:80-95.
109. Rivera F., et al. Current situation of panitumumab, matuzumab, nimotuzumab and zalutumumab. Acta Oncol. 2008, 47:9-19.
110. Scott A.M., et al. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:4071-4076.
111. Gordon M.S., et al. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. Clin. Cancer Res. 2010, 16:699-710.
112. Jin H., et al. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res. 2008, 68:4360-4368.
113. Scartozzi M., et al. Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer. Curr. Opin. Mol. Ther. 2010, 12:361-371.
114. Vearing C., et al. Concurrent binding of anti-EphA3 antibody and ephrin-A5 amplifies EphA3 signaling and downstream responses: potential as EphA3-specific tumor-targeting reagents. Cancer Res. 2005, 65:6745-6754.
115. Rizzoli R., et al. Denosumab. Nat. Rev. Drug Discov. 2010, 9:591-592.
116. Welt S., et al. Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. J. Clin. Oncol. 1994, 12:1193-1203.
117. Scott A.M., et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin. Cancer Res. 2003, 9:1639-1647.
118. Schliemann C., Neri D. Antibody-based vascular tumor targeting. Recent Results Cancer Res. 2010, 180:201-216.
119. Romond E.H., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 2005, 353:1673-1684.
120. Piccart-Gebhart M.J., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 2005, 353:1659-1672.
121. Slamon D., et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC7→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res. Treat. 2005, 94(Suppl. 1):S5.
122. Slamon D., et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. Breast Cancer Res. Treat. 2006, 100(S1):52.
123. Slamon D.J., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001, 344:783-792.
124. Hurwitz H., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350:2335-2342.
125. Hurwitz H.I., et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J. Clin. Oncol. 2005, 23:3502-3508.
126. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 2007, 25:1539-1544. Eastern Cooperative Oncology Group Study E.
127. Sandler A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 2006, 355:2542-2550.
128. Miller K., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 2007, 357:2666-2676.
129. Escudier B., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370:2103-2111.
130. Rini B.I., et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J. Clin. Oncol. 2008, 26:5422-5428.
131. Cunningham D., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 2004, 351:337-345.
132. Jonker D.J., et al. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med. 2007, 357:2040-2048.
133. Bonner J.A., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 2006, 354:567-578.
134. Vermorken J.B., et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 2008, 359:1116-1127.
135. Van Cutsem E., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol. 2007, 25:1658-1664.
136. Coiffier B., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 2002, 346:235-242.
137. Habermann T.M., et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J. Clin. Oncol. 2006, 24:3121-3127.
138. Pfreundschuh M., et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008, 9:105-116.
139. Pfreundschuh M., et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006, 7:379-391.
140. Marcus R., et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005, 105:1417-1423.
141. Hiddemann W., et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005, 106:3725-3732.
142. van Oers M.H.J., et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006, 108:3295-3301.
143. Forstpointner R., et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004, 104:3064-3071.
144. Robak T., et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J. Clin. Oncol. 2010, 28:1756-1765.